Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) by 4.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,971,048 shares of the company’s stock after buying an additional 75,670 shares during the period. Nuveen Asset Management LLC owned about 2.43% of Karyopharm Therapeutics worth $10,762,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in KPTI. State Street Corp boosted its position in shares of Karyopharm Therapeutics by 98.9% in the 1st quarter. State Street Corp now owns 10,966,701 shares of the company’s stock worth $80,825,000 after buying an additional 5,453,021 shares in the last quarter. Walleye Capital LLC boosted its position in shares of Karyopharm Therapeutics by 2,000.9% in the 2nd quarter. Walleye Capital LLC now owns 1,745,415 shares of the company’s stock worth $7,872,000 after buying an additional 1,662,337 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Karyopharm Therapeutics by 338.0% in the 1st quarter. Bank of America Corp DE now owns 1,116,230 shares of the company’s stock worth $8,227,000 after buying an additional 861,362 shares in the last quarter. ExodusPoint Capital Management LP boosted its position in shares of Karyopharm Therapeutics by 3,215.0% in the 2nd quarter. ExodusPoint Capital Management LP now owns 645,985 shares of the company’s stock worth $2,913,000 after buying an additional 626,498 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Karyopharm Therapeutics by 17.9% in the 1st quarter. Vanguard Group Inc. now owns 3,960,708 shares of the company’s stock worth $29,190,000 after buying an additional 601,901 shares in the last quarter. 96.13% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Stock Performance

KPTI opened at $3.11 on Thursday. The firm has a 50 day moving average price of $3.24 and a 200 day moving average price of $4.26. The company has a market cap of $352.49 million, a PE ratio of -1.53 and a beta of 0.04. Karyopharm Therapeutics Inc. has a 1 year low of $2.45 and a 1 year high of $8.63.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last posted its earnings results on Wednesday, February 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.09). The company had revenue of $33.58 million for the quarter, compared to analysts’ expectations of $33.88 million. On average, sell-side analysts predict that Karyopharm Therapeutics Inc. will post -1.3 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Richard A. Paulson sold 33,033 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total transaction of $100,089.99. Following the completion of the sale, the chief executive officer now owns 823,622 shares of the company’s stock, valued at approximately $2,495,574.66. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Karyopharm Therapeutics news, CEO Richard A. Paulson sold 33,033 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total value of $100,089.99. Following the completion of the sale, the chief executive officer now owns 823,622 shares of the company’s stock, valued at $2,495,574.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael Mason sold 11,205 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total transaction of $33,951.15. Following the completion of the sale, the chief financial officer now directly owns 245,361 shares of the company’s stock, valued at approximately $743,443.83. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,131 shares of company stock valued at $229,983. 10.24% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Morgan Stanley reduced their target price on shares of Karyopharm Therapeutics from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Friday, January 27th. Piper Sandler assumed coverage on shares of Karyopharm Therapeutics in a report on Thursday, January 19th. They issued an “overweight” rating and a $8.00 target price on the stock. StockNews.com upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 20th. SVB Leerink reduced their target price on shares of Karyopharm Therapeutics from $6.00 to $5.00 and set a “market perform” rating on the stock in a report on Tuesday, January 10th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, February 22nd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.50.

About Karyopharm Therapeutics

(Get Rating)

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).